Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 5/20 | 0.54 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP4B1 | P13584 | 2/20 | 0.54 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.54 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.54 |
| ▸ | CYP2A7 | P20853 | 2/20 | 0.54 |
| ▸ | CYP3A7 | P24462 | 2/20 | 0.54 |
| ▸ | CYP2F1 | P24903 | 2/20 | 0.54 |
| ▸ | CYP2C18 | P33260 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.54 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.54 |
| ▸ | CYP4F8 | P98187 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17144798 | 0.90 | CYP1A1 (0.61) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL17144737 | 0.88 | CYP1A1 (0.61) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL17145021 | 0.88 | CYP1A1 (0.62) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL28960777 | 0.88 | CYP1A1 (0.50) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL17144794 | 0.88 | CYP1A1 (0.50) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL30102579 | 0.88 | CYP1A1 (0.50) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL30102582 | 0.88 | CYP1A1 (0.50) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| Hydrochloric Acid SCHEMBL17144266 | 0.87 | CYP1A1 (0.49) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL17145017 | 0.86 | KDM4E (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17144826 | 0.86 | CYP1A1 (0.54) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017475-B2 | Anti-vasculature and anti-tubulin combretastatin analogs for treatment of cancer | XAVIER UNIVERSITY OF LOUSIANA (US) | 2018-07-10 | — | — | US | claimed |
| US-20170044103-A1 | ANTI-VASCULATURE AND ANTI-TUBULIN COMBRETASTATIN ANALOGS FOR TREATMENT OF CANCER | XAVIER UNIVERSITY OF LOUISIANA | 2017-02-16 | — | — | US | claimed |
| WO-2015153252-A1 | ANTI-VASCULATURE AND ANTI-TUBULIN COMBRETASTATIN ANALOGS FOR TREATMENT OF CANCER | XAVIER UNIVERSITY OF LOUISIANA (US) | 2015-10-08 | — | — | WO | claimed |
| US-10017475-B2 | Anti-vasculature and anti-tubulin combretastatin analogs for treatment of cancer | XAVIER UNIVERSITY OF LOUSIANA (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170044103-A1 | ANTI-VASCULATURE AND ANTI-TUBULIN COMBRETASTATIN ANALOGS FOR TREATMENT OF CANCER | XAVIER UNIVERSITY OF LOUISIANA | 2017-02-16 | — | — | US | disclosed |
| US-20170044103-A1 | ANTI-VASCULATURE AND ANTI-TUBULIN COMBRETASTATIN ANALOGS FOR TREATMENT OF CANCER | XAVIER UNIVERSITY OF LOUISIANA | 2017-02-16 | — | — | US | disclosed |
| WO-2015153252-A1 | ANTI-VASCULATURE AND ANTI-TUBULIN COMBRETASTATIN ANALOGS FOR TREATMENT OF CANCER | XAVIER UNIVERSITY OF LOUISIANA (US) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044103-A1 | ANTI-VASCULATURE AND ANTI-TUBULIN COMBRETASTATIN ANALOGS FOR TREATMENT OF CANCER | FLT4, TUBB3, TUBA4A | CYP1A1 4870/4885CYP1B1 4689/4885CYP1A2 4850/4885 |
| US-10017475-B2 | Anti-vasculature and anti-tubulin combretastatin analogs for treatment of cancer | FLT4, TUBB3, TUBA4A | CYP1A1 4870/4885CYP1B1 4689/4885CYP1A2 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.